Abstract Long-term anti-epileptic drug (AED) therapy is associated with increased fracture risk. This study tested whether substituting the newer AED levetiracetam has less adverse effects on bone than older AEDs. An open-label randomized comparative trial. Participants had ''failed'' initial monotherapy for partial epilepsy and were randomized to substitution monotherapy with levetiracetam or an older AED (carbamazepine or valproate sodium). Bone health assessments, performed at 3 and 15 months, included areal bone mineral density (aBMD) and content at lumbar spine (LS), total hip (TH), forearm (FA), and femoral neck (FN), radial and tibial peripheral quantitative computed tomography and serum bone turnover markers. Main outcomes were changes by treatment group in aBMD at LS, TH, and FA, radial and tibial trabecular BMD and cortical thickness. 70/84 patients completed assessments (40 in levetiracetam-and 30 in older AED group). Withingroup analyses showed decreases in both groups in LS (-9.0 %; p \ 0.001 in levetiracetam vs. -9.8 %; p \ 0.001 in older AED group), FA (-1.46 %; p \ 0.001 vs. -0.96 %; p \ 0.001, respectively) and radial trabecular BMD (-1.46 %; p = 0.048 and -2.31 %; p = 0.013, respectively). C-terminal telopeptides of type I collagen (bCTX; bone resorption marker) decreased in both groups (-16.1 %; p = 0.021 vs. -15.2 %; p = 0.028, respectively) whereas procollagen I N-terminal peptide (PINP; bone formation marker) decreased in older AED group (-27.3 %; p = 0.008). The treatment groups did not differ in any of these measures. In conclusion, use of both levetiracetam and older AEDs was associated with bone loss over 1 year at clinically relevant fracture sites and a reduction in bone turnover.
Introduction
Chronic antiepileptic drug (AED) therapy is associated with bone disease and increased fracture risk [1] . Several studies have revealed this association but the mechanisms remain controversial [2] [3] [4] [5] [6] [7] [8] . Decreased bone mineral density (BMD), the most significant predictor of fracture risk, has been observed in patients using ''older generation'' AEDs, particularly inducers of cytochrome p450 (CYP450) enzymes; carbamazepine, phenytoin, phenobarbital, and primidone [9] . The impact of the older AED valproate, a CYP450 inhibitor, on bone is still controversial, but a number of studies also show an association of treatment with this drug with decreased BMD [4] [5] [6] 10] . It is still unclear whether the ''newer generation'' AEDs that have been introduced into practice over the last two decades, including gabapentin, lamotrigine, topiramate, tiagabine, oxcarbazepine, levetiracetam, and zonisamide, adversely affect bone health.
The American Academy of Neurology (AAN) subcommittee report observed that newer AEDs were ''equivalent'' in controlling seizures, but might be better tolerated (i.e., have less adverse effects) than older AEDs [11] . Of particular relevance, the newer AEDs do not enhance or inhibit liver enzymes. Evidence from uncontrolled trials has raised the possibility that lamotrigine has limited negative effects on bone [5, 6, 12, 13] . In contrast, some studies report low bone density in people on longterm treatment with oxcarbazepine [14] , gabapentin [3] , and topiramate [15] . Levetiracetam is a ''new generation'' AED that is structurally and mechanistically distinct to other AEDs. It has a favorable efficacy, tolerability, and pharmacokinetic profile [16, 17] . It therefore potentially has less adverse effects on bone but data are limited. A prospective cohort study reported no significant bone loss in drug-naïve epilepsy patients treated with levetiracetam [18] . A cross-sectional study, in contrast, reported lower BMD in patients taking levetiracetam compared to those taking topiramate, lamotrigine, carbamazepine, or valproate monotherapy [19] .
Herein, we report a 12-month randomized comparative study (RCT) aimed at testing the hypothesis that patients randomized to treatment with levetiracetam will show, on serial assessments performed 12 months apart, less changes in: (1) areal bone mineral density (aBMD) at clinically relevant sites; (2) bone volumetric density and structure; (3) serum markers of bone turnover; compared to those randomized to treatment with an older AED (carbamazepine or sodium valproate). The null hypothesis was that there is no difference between the interventions.
Methods Patients
This was a pragmatic, single-centre, prospective, open-label study with blinded endpoint ascertainment. Eligible patients were recruited from the KONQUEST study (Keppra versus Older AEDs evaluating Neuropsychiatric, Neurocognitive, and QUality of life outcomes in treatment of Epilepsy as Substitution monoTherapy) [20] . Exclusion criteria were a history of bone disease; a treatment history of glucocorticoids, chemotherapy, or other medications which could affect bone density; a history of tumor or other medical morbidity known to affect bone health; pregnancy, breast feeding or planned pregnancy in the next year.
Randomization
Enrolled patients had ''failed'' initial monotherapy for partial epilepsy with an ''older'' AED (carbamazepine, valproate, or phenytoin) and were randomized to substitution monotherapy treatment with levetiracetam or another older AED, i.e., controlled-release carbamazepine (Tegretol Ò CR) or enteric-coated sodium valproate (Epilim Ò ). If the initial AED treatment had been carbamazepine or phenytoin the patient was randomized to levetiracetam or valproate, and if the initial AED treatment was valproate the patient was randomized to levetiracetam or carbamazepine. Details of randomization are described in Hakami et al. [20] . The primary endpoints of the KONQUEST study were the proportions of patients who showed improvement in depression symptoms and quality of life at 3 months following randomization [20] . Hence a balanced randomization schedule, based upon baseline Hospital Anxiety and Depression Scale (HADS) [21] depression score permuted blocks, was used to ensure that the two treatment groups were equivalent with regard to the numbers of patients reporting depressive symptomatology (HADS depression score [7) at baseline. Permuted blocks ensured a balance after every 4th treatment allocation, within each level of baseline scores ( Fig. 1 in Hakami et al. [20] ). The bone health measures were not considered in the randomization, which was conducted by a research scientist who had no contact with study patients. Physicians screening and enrolling patients, and scientists performing and analyzing the bone health measures, were blinded to the patient's treatment allocation.
Treatment
During the initial four-week titration period following randomization, the initial AED was weaned and the study drug increased in two weekly step-ups to a target dose of 1000 mg per day for levetiracetam, 1000 mg per day for valproate, and 400 mg per day for carbamazepine. After this time, dose adjustments by the treating neurologist were allowed if the patient had further seizures or if there were issues with tolerability. If seizures were unable to be controlled with monotherapy with the study drug, another AED could be added. If intolerable drug side effects persisted, the patient could be withdrawn from the study medication and treated with a different AED. Patients continued to be followed and received all scheduled assessments for the 12-month post-randomization period irrespective of treatment changes.
Outcome Assessments
The main bone outcomes were changes over 12 months by treatment group in (1) aBMD at lumbar spine (LS), total hip (TH), and forearm (FA); (2) trabecular BMD and cortical thickness of the non-dominant radius and tibia; and (3) serum levels of bone turnover markers. Exploratory outcomes were changes in FN aBMD and total body bone mineral content (TB BMC) on DXA and strength-strain index (SSIp) on pQCT scanning. Assessments were performed at 3 months following randomization (to allow time for dose titration of the study drug and weaning of the previous AED to be completed) and repeated 12 months later (i.e., 15 months post-randomization).
The assessments included:
1. Dual energy X-ray absorptiometry (DXA) using Hologic QDR Ò 4500A densitometer (Hologic Inc., Bedford MA, 01730 USA) for aBMD and body composition [22] . The coefficient of variation for aBMD using the Hologic spine phantom was 0.36-0.37 % throughout the duration of the study and there was no significant drift in mean values. 2. Peripheral quantitative computed tomography (pQCT) for assessment of trabecular and cortical bone volumetric density and geometry at non-dominant tibia and radius using Stratec 3000 XCT version 5. 
Statistical Analysis
The sample size calculation was based upon the depression scores primary endpoint of the KONQUEST study, as described in Hakami et al. [20] . The study was not specifically powered for bone health measures, which were secondary endpoints. Analyses were undertaken on per protocol basis. Patients who did not attend for their 12-month follow-up bone health assessments were excluded from the analysis. The analysis comprised adjusted comparison between the treatment groups for 12-month percentage change in aBMD at LS, TH, and FA; trabecular BMD and cortical thickness of the non-dominant radius and tibia; and serum levels of bone turnover markers. The changes in LS, TH, FA, and FN aBMD in the combined treatment groups were also compared to those in a healthy untreated reference group. The DXA and pQCT measures were adjusted for age, baseline height and weight, and time interval. Paired t tests and independent t tests were utilized to assess mean within-group absolute change and betweengroup differences, respectively. Categorical variables were compared using Chi-square (v 2 )/Fisher's exact test for repeated measures. As the two laboratories used different assay methodology and laboratory references (Table e-1) , agreements between the results measuring paired samples in the two laboratories were assessed using: Pearson's correlation and Bland-Altman analysis (see supplementary material).
Mixed-effects restricted maximum likelihood (REML) regression analysis was fitted to examine the effect of specific factors and covariates on the outcomes of interest. Factors examined included treatment groups, sex and menopausal status, and alcohol consumption. Covariates included age, height, weight change, follow-up interval, calcium intake, and life-time smoking. REML analysis was utilized due to its advantages over standard linear modeling (where all observations are assumed to be independent) and accounts for both the within-group and between-group variation in the dataset.
Results were presented as mean (SD)/or median (IQR) and percentage of change. Level of significance was set at \0.05. However, due to the number of comparisons between main outcomes, level of significance for Univariate analysis was adjusted using the Bonferroni adjustment and set at 0.01. All analyses were performed using the statistical package Stata SE/10Á1 for Windows (StataCorp, TX, USA).
Ethics Approval and Registration
The (Table 1) . Figure 1 is a flow chart for enrolled patients. Thirty-one of 45 patients randomized to levetiracetam (69 %) and 20 of 39 patients randomized to older AEDs (51 %) completed the study on assigned monotherapy. In total, 14/84 (16.7 %) of patients withdrew or died during the study, and this did not significantly differ between the treatment groups (five randomized to levetiracetam, three to carbamazepine and six to valproate sodium). Withdrawals from the study were due to -Non-compliance with the study procedures-10 patients (two levetiracetam, two carbamazepine, and six valproate); -Medication side effects-one patient (levetiracetam, balance problem, and poor seizure control); -Conversion to high grade brain tumor-one patient (levetiracetam); -Death-two patients (one patient taking carbamazepine died of sudden unexpected death in epilepsy (SUDEP), one patient taking levetiracetam died of carcinoma of the stomach).
Main Bone Outcomes
On DXA scanning, there was no difference between the treatment groups in the percentage change in aBMD from baseline to 12 months at LS (-9.0 % in the levetiracetam group vs. -9.8 % in the older AED group; p = 0.53, independent t test), FA (-1.46 vs. -0.96 %, respectively; p = 0.14, independent t test), or TH (-0.21 vs. -0 .84 %, respectively; p = 0.11, independent t test). On pQCT, there was no significant difference between the treatment groups in the percentage change in trabecular BMD and cortical thickness at both non-dominant radius and tibia sites (Table 4) . Within-group analysis, however, showed a decrease in both groups in LS aBMD (-9.0 %; p \ 0.001 in the levetiracetam group and -9.8 %; p \ 0.001 in the older AED group, paired t-test) and FA (-1.46 %; p \ 0.001 in the levetiracetam group and -0.96 %; p \ 0.001 in the older AED group, paired t test) ( Table 2 ). TH aBMD decreased in the older AED group (-0 .84 %; p \ 0.001, paired t-test) but not in the levetiracetam group (-0.21 %; p = 0.56, paired t test). Both groups also showed a significant decrease in serum bCTX levels, a marker of bone resorption (-16.1 %; p = 0.021 in the levetiracetam group and -15.2 %; p = 0.028 in the older AED group, paired t test). Serum P1NP concentrations, marker of bone formation, significantly decreased in the older AED group (-27.3 %; p = 0.008, paired t test) and showed a trend towards decrease in the levetiracetam group (-20.9 %; p = 0.14, paired t test) ( Table 3) . 
Exploratory Outcomes
There was a difference between the treatment groups in the change in FN aBMD (-0.47 % in the levetiracetam group vs. -1.45 % in the older AED group; p = 0.005, independent t test) and the whole body BMC (-0.16 vs. 0.60 %, respectively; p = 0.012, independent t test) ( Table 2 ). Males and females in either group were not different in the changes in LS, FA, TH, or FN aBMD (p C 0.05). On pQCT scanning, patients randomized to an Abmd areal bone mineral density, TB BMC total body bone mineral content; g/cm 2 grams per square centimeter, g/cm grams per centimeter, SD standard deviation; -decrease; ? increase The comparison of within-group mean change and percentage change and between-group difference over a 12-month period in the changes in serum markers of bone turnover, vitamin D, intact parathyroid hormone and calcium. Significant within groups change or between groups difference is indicated by * for p \ 0.05, ** for p \ 0.01, and *** for p \ 0.001 bCTX C-terminal telopeptides of type I collagen, PINP procollagen 1 N-terminal peptide; 25OHD 25-hydroxyvitamin-D (25OHD), (1,25(OH)2D) 1,25-dihydroxyvitamin-D, iPTH intact parathyroid hormone, ng/ml nanograms per milliliter, lg/l micrograms per liter, nmol/l nanomoles per liter, pmol/l picomoles per liter, mmol/l millimoles per liter, SD standard deviation, -decrease, ? increase older AED had significant decreases in all measures of trabecular bone as well as cortical BMD and strength-strain index (SSIp) at the non-dominant radius (Table 4) . Compared to those randomized to an older AED, patients randomized to levetiracetam had higher cortical BMD, but lower total bone area Cortical and periosteal circumference at the non-dominant radius (Table 4) . Patients randomized to an older AED had higher SSIp and endosteal circumference at the non-dominant tibia (supplementary material- Table e-3) .
REML Analysis for Factors and Covariates Affecting Bone Density
Mixed-effects REML regression analysis was fitted to examine effects of some factors and covariates on areal bone mineral density (aBMD) at the lumbar spine, forearm, total hip, and femoral neck [details of REML analysis of the lumbar spine aBMD are described in the supplementary material (Table e-4) ]. The analysis showed that 88 % of variance was attributed to between-patient differences. The comparison of within-group mean change and percentage change and between-group difference over a 12-month period in the changes in pQCT measures at the non-dominant radius. Significant within groups change or between groups difference is indicated by * for p \ 0.05, ** for p \ 0.01, and *** for p \ 0.001 BMD bone mineral density, BMC bone mineral content, mm 2 millimeter square, mg/mm milligram per millimeter, mg/ccm milligrams per cubic centimeter, SD standard deviation, -decrease, ? increase, SSIp polar strength-strain index Post-menopausal female status was a borderline significant predictor for the change in the lumbar spine aBMD (p = 0.047, v 2 test). The REML analysis for aBMD change at the other sites (forearm, total hip, and femoral neck) also showed that 88 % of the unexplained residual variation existed at the between-patient level. Weight change showed a trend towards significance at three sites: the lumbar spine (p = 0.071, v 2 test), forearm (p = 0.055, v 2 test), and femoral neck (p = 0.044, v 2 test).
Comparison of Serial Changes with a Healthy, Untreated Reference Group
It was not ethically feasible to include an untreated control group in the trial; hence a reference group was included to test for instrument stability. Data for the reference group were obtained from J.D Wark research group's database at the University of Melbourne, Australia. All participants were scanned on the same dual energy x-ray absorptiometry (DXA) and were scanned contemporaneously with the clinical trial participants. Patients in the treatment groups who completed the 15-month assessment [total = 70, mean (SD) age: 43.7 (17.9) years] were compared with healthy reference subjects [n = 71: mean age 41.7 (15.1) years] for the changes in aBMD on DXA scanning.
Patients in the treatment group were predominantly male (61.4 vs. 25.3 %; p \ 0.001, v 2 test) and had shorter time to follow-up scan [median (IQR): 14.8 (13.0-18.7) vs. 26.9 (24.8-32.6), p \ 0Á001, Mann-Whitney test) compared to healthy subjects. The changes in adjusted aBMD were different between the treatment group and reference group at the LS (-9.4 vs. -0.9 %, respectively; p \ 0.001, independent t test), FA (-1.24 vs. -0.40 %, respectively; p \ 0.001, independent t test) and FN (-0.87 vs. -0.02 %, respectively; p \ 0.001, independent t test). The groups did not differ in the TH aBMD change (-0.45 vs. -0.41 %, respectively; p = 0.852, independent t test).
Discussion
To our knowledge, this is the first RCT to compare the effects of different AEDs on longitudinal measures of bone health. Concern about possible adverse effects of chronic AED treatment, particularly with the older AEDs, has become increasingly prominent amongst clinicians and epilepsy sufferers and their families. Over the last two decades, several newer AEDs have been approved for clinical use, with hope that these may have less adverse effects. Levetiracetam is a newer generation AED with a unique mechanism of action, binding to the SV2A receptor on neuronal synaptic vesicles where it is believed to inhibit vesicular exocytosis and thereby reduce synaptic excitability. The drug does not enhance liver enzymes or result in other metabolic changes [16, 17] . Although efficacy and tolerability of levetiracetam have been evaluated in several controlled trials [24] [25] [26] [27] [28] [29] , there has been no previous randomized controlled trial examining effects of levetiracetam on bone health.
In this study, patients with epilepsy were randomized to monotherapy with one of two older AEDs (carbamazepine or valproate) or to treatment with the newer AED levetiracetam. AED treatments were compared extensively with serial assessments performed 12 months apart, including historical bone health risk factors, areal bone mineral measures (with DXA), bone volumetric density and structure (with pQCT), and biochemical markers of bone turnover. Carbamazepine and valproate were analyzed as a single group despite their different mechanisms of action, as previous studies suggested that both have bone effects. A number of studies report that carbamazepine, valproate, and lamotrigine monotherapy in premenopausal women with epilepsy do not differ in their adverse effects on 25-OHD, PTH, markers of bone turnover or bone mineral density [5, 6] .
We found that patients randomized to both the older AEDs and to levetiracetam showed changes in bone density and structure on serial DXA and pQCT studies. In both treatment groups, there were significant decreases over 12 months in aBMD at the lumbar spine, forearm, and femoral neck, common sites of fracture in patients with osteoporosis. In both treatment groups there were decreases in trabecular BMD, total trabecular bone area, total cortical bone area, and polar strength-strain index at the nondominant radius. The latter is an index of long bone bending strength. These findings suggest that chronic treatment with both the older AEDs and the newer generation AED, levetiracetam, is associated with adverse effects on bone health. Similarly, a retrospective study found that in 17 subjects treated with levetiracetam, 70 % had low BMD [19] . In contrast, levetiracetam monotherapy in 61 patients with recent-onset epilepsy was associated with an increase in BMD at the lumbar spine with no change in biochemical bone markers [18] . The latter study included individuals at age range of 13-55 years some of whom were continuing to increase BMD and therefore the findings are likely related to the age as opposed to the direct effect of levetiracetam [30] but this is unlikely to be the sole explanation for the difference in findings.
The overall magnitude of effect, and the nature and pathogenesis of bone disease affecting patients taking AEDs remains to be determined. Based on the relatively small amount of longitudinal data available, chronic AED use may result in approximately 1.5-2.0 % annual bone loss at clinically relevant fracture sites [2] . However, this study showed a decrease in BMD over a 12-month interval (-9.4 % in the lumbar spine, -1.24 % in forearm, and -0.87 % in femoral neck), which was greater than those in healthy reference subjects of similar age and not taking any medications (-0.9 % in the lumbar spine, -0.4 % in forearm, and -0.02 % in femoral neck). This bone loss is potentially of clinical significance and warrants further study to determine whether this rate of loss is sustained longer-term.
We also found that patients randomized to older AED treatment had a decrease in serum levels of bCTX and PINP, indicating reduced overall bone turnover. Patients randomized to levetiracetam treatment had a decrease in serum levels of bCTX, indicative of reduced bone resorption. The mean 25-OHD level was in the low sufficient/ replete range (50-80 nmol/L) in both treatment groups over the study period, without significant change over time. The mechanism underlying bone deficits in patients taking AEDs remains not understood. One plausible hypothesis is that, given that all AEDs ultimately act to decrease neuronal excitability, they also have analogous effects on bone cells, with adverse consequences on bone health. This hypothesis would be consistent with the finding in this study that AED treatments reduced not only bone formation but also bone resorption. Another hypothesis is that the mechanism of bone loss could independently (apart of the potential effect of AEDs) be related to epilepsy itself, which require further investigation.
Unlike other studies in the literature that reported levetiracetam in patients with new onset epilepsy, our study included a clinically important, but understudied group of patients in whom initial treatment with an ''older'' AED had ''failed'' due to either inadequate seizure control or intolerable AED side effects. Therefore, it cannot be excluded that the bone loss was a result of poor seizure control and/or delayed adverse effect of pre-randomization drug(s). It should also be acknowledged that, because carbamazepine and valproate have different effects on cytochrome P450 enzymes, the two drugs may have variable effects on bone and therefore the combined analysis would make the data difficult to interpret. However, final sample size of subjects in subgroups who continued to receive the AED to which they were randomized and were taking that AED in monotherapy was very small (8 for carbamazepine and 12 for valproate). The subjects in the two subgroups were also heterogeneous, including men and women (pre-and post-menopausal) over a wide age range. Therefore, it may not be valid to analyze data separately for carbamazepine and valproate groups and to draw clinically relevant conclusions.
While this unique study has a number of strengths, including its RCT design, it also has limitations. First, the number of participants studied was relatively small, and not primarily powered to detect differences in bone health measures between treatment groups. The study was also limited by the relatively short-term follow-up period and the clinically mandated changes in AED treatment regimes in some patients in the interval. Analysis of the serum bone turnover markers in two different laboratories is a limitation, which we took careful steps to minimize. Another potential limitation is that the treatments were open-labeled, which means that there was greater potential for information bias arising from patient, doctor and investigator preconceptions. However, the outcome assessors were blinded to the treatment assignment.
In conclusion, this RCT, in which patients were randomized to monotherapy treatment with either the newer AED levetiracetam or one of the older AEDs, carbamazepine or valproate, demonstrated significant bone loss at clinically relevant sites over 12 months, accompanied by changes in the serum levels of bone turnover markers. Although this study was not sufficiently powered to detect significant differences between the treatment groups, the results highlight the need for further research characterizing the mechanisms underlying the adverse effects of AEDs on bone health, for further longitudinal comparative studies of different specific treatment options, and for patients and clinicians to be informed of the potential implications of AED treatment on bone health and fracture risk, and the need to monitor for this adverse effect.
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